Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a sell rating to a hold rating in a report issued on Monday.

Pieris Pharmaceuticals Trading Down 0.1 %

Shares of Pieris Pharmaceuticals stock opened at $16.10 on Monday. The stock has a fifty day simple moving average of $16.69 and a 200 day simple moving average of $13.70. Pieris Pharmaceuticals has a 12-month low of $6.20 and a 12-month high of $22.32. The company has a market capitalization of $21.25 million, a P/E ratio of -0.86 and a beta of 0.66.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($2.76) earnings per share (EPS) for the quarter. Pieris Pharmaceuticals had a negative net margin of 39.71% and a negative return on equity of 101.29%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. BML Capital Management LLC acquired a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals accounts for approximately 0.4% of BML Capital Management LLC’s investment portfolio, making the stock its 21st biggest position. BML Capital Management LLC owned 3.19% of Pieris Pharmaceuticals as of its most recent filing with the SEC. 40.11% of the stock is owned by institutional investors.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.